[1] Rubinstein, E., Kollef, M.H. and Nathwani, D. (2008) Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases, 46, S378-S385.
http://dx.doi.org/10.1086/533594
[2] Hiramatsu, K. and Niederman, M.S. (2005) Health-Care-Associated Pneumonia: A New Therapeutic Paradigm. Chest, 128, 3784-3787.
http://dx.doi.org/10.1378/chest.128.6.3784
[3] Kollef, M.H., Shorr, A., Tabak, Y.P., Gupta, V., Liu, L.Z. and Johannes, R.S. (2005) Epidemiology and Outcomes of Health-Care-Associated Pneumonia: Results from a Large US Database of Culture-Positive Pneumonia. Chest, 128, 3854-3862.
http://dx.doi.org/10.1378/chest.128.6.3854
[4] American Thoracic Society, Infectious Diseases Society of America (2005) Guidelines for the Management of Adults with Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 171, 388-416.
http://dx.doi.org/10.1164/rccm.200405-644ST
[5] Micek, S.T., Kollef, K.E., Reichley, R.M., Roubinian, N. and Kollef, M.H. (2007) Health Care-Associated Pneumonia and Community-Acquired Pneumonia: A Single-Center Experience. Antimicrobial Agents and Chemotherapy, 51, 3568-3573.
http://dx.doi.org/10.1128/AAC.00851-07
[6] David, M.Z. and Daum, R.S. (2010) Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic. Clinical Microbiology Reviews, 23, 616-687.
http://dx.doi.org/10.1128/CMR.00081-09
[7] Klein, E. and Smith, D.L. (2007) Laxminarayan R: Hospitalizations and Deaths Caused by Methicillin-Resistant Staphylococcus aureus, United States, 1999-2005. Emerging Infectious Diseases Journal, 13, 1840-1846.
http://dx.doi.org/10.3201/eid1312.070629
[8] Jones, R.N. (2010) Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases, 51, S81-S87.
http://dx.doi.org/10.1086/653053
[9] Kawasaki, S., Aoki, N., Kikuchi, H., Nakayama, H., Saito, N., Shimada H., et al. (2011) Clinical and Microbiological Evaluation of Hemodialysis-Associated Pneumonia (HDAP): Should HDAP Be Included in Healthcare-Associated Pneumonia? Journal of Infection and Chemotherapy, 17, 640-645.
http://dx.doi.org/10.1007/s10156-011-0228-z
[10] Chastre, J. and Fagon, J.Y. (2002) Ventilator-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 165, 867-903.
http://dx.doi.org/10.1164/ajrccm.165.7.2105078
[11] Tablan, O.C., Anderson, L.J., Besser, R., Bridges, C. and Hajjeh, R. (2004) CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for Preventing Health-Care-Associated Pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recommendations and Reports, 53, 1-36.
[12] Craven, D.E. and Steger, K.A. (1996) Nosocomial Pneumonia in Mechanically Ventilated Adult Patients: Epidemiology and Prevention in 1996. Seminars in Respiratory Infections, 11, 32-53.
[13] Weinstein, R.A. (1991) Epidemiology and Control of Nosocomial Infections in Adult Intensive Care Units. American Journal of Medicine, 91, 179S-184S.
http://dx.doi.org/10.1016/0002-9343(91)90366-6
[14] Torres, A., Gatell, J.M., Aznar, E., El-Ebiary, M., Puig de la Bellacasa, J., Gonzalez, J., et al. (1995) Re-Intubation Increases the Risk of Nosocomial Pneumonia in Patients Needing Mechanical Ventilation. American Journal of Respiratory and Critical Care Medicine, 152, 137-141.
http://dx.doi.org/10.1164/ajrccm.152.1.7599812
[15] Klevens, R.M., Edwards, J.R., Richards Jr., C.L., Horan, T.C., Gaynes, R.P., Pollock, D.A., et al. (2007) Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002. Public Health Reports, 122, 160-166.
[16] Shorr, A.F., Tabak, Y.P., Gupta, V., Johannes, R.S., Liu, L.Z. and Kollef, M.H. (2006) Morbidity and Cost Burden of Methicillin-Resistant Staphylococcus aureus in Early Onset Ventilator-Associated Pneumonia. Critical Care, 10, R97.
http://dx.doi.org/10.1186/cc4934
[17] Shorr, A.F., Haque, N., Taneja, C., Zervos, M., Lamerato, L., Kothari, S., et al. (2010) Clinical and Economic Outcomes for Patients with Health Care Associated Staphylococcus aureus Pneumonia. Journal of Clinical Microbiology, 48, 3258-3262.
http://dx.doi.org/10.1128/JCM.02529-09
[18] Abramson, M.A. and Sexton, D.J. (1999) Nosocomial Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Primary Bacteremia: At What Costs? Infection Control & Hospital Epidemiology, 20, 408-411.
http://dx.doi.org/10.1086/501641
[19] Carbon, C. (1999) Costs of Treating Infections Caused by Methicillin-Resistant Staphylococci and Vancomycin-Resistant Enterococci. Journal of Antimicrobial Chemotherapy, 44, 31-36.
http://dx.doi.org/10.1093/jac/44.suppl_1.31
[20] Rubin, R.J., Harrington, C.A., Poon, A., Dietrich, K., Greene, J.A. and Moiduddin, A. (1999) The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals. Emerging Infectious Diseases Journal, 5, 9-17.
http://dx.doi.org/10.3201/eid0501.990102
[21] Li, J., Willke, R., Pinto, L., Rittenhouse, B.E., Rybak, M.J., Pleil, A.M., et al. (2001) Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin-Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial. Pharmacotherapy, 21, 263-274.
http://dx.doi.org/10.1592/phco.21.3.263.34198
[22] Houck, P.M., Bratzler, D.W., Nsa, W., Ma, A. and Bartlett, J.G. (2004) Timing of Antibiotic Administration and Outcomes for Medicare Patients Hospitalized with Community-Acquired Pneumonia. Archives of Internal Medicine, 164, 637-644.
http://dx.doi.org/10.1001/archinte.164.6.637
[23] Rello, J., Molano, D., Villabon, M., Reina, R., Rita-Quispe, R. and Previgliano, I. (2013) Differences in Hospital- and Ventilator-Associated Pneumonia Due to Staphylococcus aureus (Methicillin-Susceptible and Methicillin-Resistant) between Europe and Latin America: A Comparison of the EUVAP and LATINVAP Study Cohorts. Medicina Intensiva, 37, 241-247.
http://dx.doi.org/10.1016/j.medin.2012.04.008
[24] Rivera, A.M. and Boucher, H.W. (2011) Current Concepts in Antimicrobial Therapy against Select Gram-Positive Organisms: Methicillin-Resistant Staphylococcus aureus, Penicillin-Resistant Pneumococci, and Vancomycin-Resistant Enterococci. Mayo Clinic Proceedings, 86, 1230-1242.
http://dx.doi.org/10.4065/mcp.2011.0514
[25] Gonzalez, C., Rubio, M., Romero-Vivas, J., Gonzalez, M. and Picazo, J.J. (1999) Bacteremic Pneumonia Due to Staphylococcus aureus: A Comparison of Disease Caused by Methicillin-Resistant and Methicillin-Susceptible Organisms. Clinical Infectious Diseases, 29, 1171-1177.
http://dx.doi.org/10.1086/313440
[26] Rodvold, K.A. and McConeghy, K.W. (2014) Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future. Clinical Infectious Diseases, 58, S20-S27.
http://dx.doi.org/10.1093/cid/cit614
[27] Bodi, M., Ardanuy, C. and Rello, J. (2001) Impact of Gram-Positive Resistance on Outcome of Nosocomial Pneumonia. Critical Care Medicine, 29, N82-N86.
http://dx.doi.org/10.1097/00003246-200104001-00005
[28] Wunderink, R.G., Rello, J., Cammarata, S.K., Croos-Dabrera, R.V. and Kollef, M.H. (2003) Linezolid vs Vancomycin: Analysis of Two Double-Blind Studies of Patients with Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest, 124, 1789-1797.
[29] Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., et al. (1997) Dissemination in Japanese Hospitals of Strains of Staphylococcus aureus Heterogeneously Resistant to Vancomycin. The Lancet, 350, 1670-1673.
http://dx.doi.org/10.1016/S0140-6736(97)07324-8
[30] Ariza, J., Pujol, M., Cabo, J., Pena, C., Fernandez, N., Linares, J., et al. (1999) Vancomycin in Surgical Infections to Methicillin-Resistant Staphylococcus aureus with Heterogenous Resistance to Vancomycin. The Lancet, 353, 1587-1588.
http://dx.doi.org/10.1016/S0140-6736(99)01017-X
[31] Sieradzki, K., Villari, P. and Tomasz, A. (1998) Low-Level Teicoplanin Resistance and Heteroresistance to Vancomycin. Annals of Internal Medicine, 128, 245.
http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00021
[32] Sieradzki, K., Roberts, R.B., Haber, S.W. and Tomasz, A. (1999) The Development of Vancomycin Resistance in a Patient with Methicillin-Resistant Staphylococcus aureus Infection. The New England Journal of Medicine, 340, 517-523.
http://dx.doi.org/10.1056/NEJM199902183400704
[33] Wong, S.S.Y., Ho, P.L., Woo, P.C.Y. and Yuen, K.Y. (1999) Bacteremia Caused by Staphylococci with Inducible Vancomycin Heteroresistance. Clinical Infectious Diseases, 29, 760-767.
http://dx.doi.org/10.1086/520429
[34] Centers for Disease Control and Prevention (1997) Update: Staphylococcus aureus with Reduced Susceptibility to Vancomycin—United States. Morbidity and Mortality Weekly Report, 46, 813-815.
[35] Chaudhary, M. and Payasi, A. (2013) Inhibition of in Vitro mecA Gene Transfer among Indian Clinical Isolates of Staphylococus aureus. The Journal of Applied Biochemistry, 106, 133-139.
[36] Chaudhary, M., Patnaik, S.K. and Payasi, A. (2014) Evaluation of Different Drugs in Down-Regulation of Efflux Pump Genes Expression in Methicillin-Resistant Staphylococcus aureus Strains. American Journal of Infectious Diseases, 10, 184-189.
http://dx.doi.org/10.3844/ajidsp.2014.184.189
[37] Chaudhary, M., Patnaik, S.K. and Payasi, A. (2014) Inhibition of Panton-Valentine Leukocidin Toxin Induced Neutrophil Cell Lysis by Vancoplus in Methicillin-Resistant Staphylococcus aureus Infections. American Journal of Infectious Diseases, 10, 154-163.
http://dx.doi.org/10.3844/ajidsp.2014.154.163
[38] Chaudhary, M. and Payasi, A. (2015) Taming Wall Teichoic Acid Multi Drug Resistance in Gram Positive Pathogens. Journal of Chemical and Pharmaceutical Research, 7, 18-23.
[39] Chaudhary, M. and Payasi, A. (2015) Vancoplus Kinetic Study in Vancomycin Resistant Staphylococcus aureus. International Journal of Pharmaceutical Sciences Review and Research, 31, 135-142.
[40] Dalfino, L., Bruno, F., Colizza, S., Concia, E., Novelii, A., Rebecchi, F., et al. (2014) Cost of Care and Antibiotic Prescribing Attitudes for Community-Acquired Complicated Intra-Abdominal Infections in Italy: A Retrospective Study. World Journal of Emergency Surgery, 9, 39.
http://dx.doi.org/10.1186/1749-7922-9-39
[41] Gaynes, R. and Edwards, J.R. (2005) Overview of Nosocomial Infections Caused by Gram-Negative Bacilli. Clinical Infectious Diseases, 41, 848-854.
http://dx.doi.org/10.1086/432803
[42] Kallen, A.J., Mu, Y., Bulens, S., Reingold, A., Petit, S., Gershman, K., et al. (2010) Health Care-Associated Invasive MRSA Infections, 2005-2008. Journal of the American Medical Association, 304, 641-648.
http://dx.doi.org/10.1001/jama.2010.1115
[43] Johnson, A.P., Davies, J., Guy, R., Abernethy, J., Sheridan, E., Pearson, A., et al. (2012) Mandatory Surveillance of Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteraemia in England: The First 10 Years. Journal of Antimicrobial Chemotherapy, 67, 802-809.
http://dx.doi.org/10.1093/jac/dkr561
[44] Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K. and Gorwitz, R.J. (2011) Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases, 52, e18-e55.
http://dx.doi.org/10.1093/cid/ciq146
[45] Paul, M., Bishara, J., Yahav, D., Goldberg, E., Neuberger, A., Ghanem-Zoubi, N., et al. (2015) Trimethoprim-Sulfamethoxazole versus Vancomycin for Severe Infections Caused by Meticillin-Resistant Staphylococcus aureus: Randomised Controlled Trial. British Medical Journal, 350, h2219.
http://dx.doi.org/10.1136/bmj.h2219
[46] Sakoulas, G., Moellering Jr., R.C. and Eliopoulos, G.M. (2006) Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy. Clinical Infectious Diseases, 42, S40-S50.
http://dx.doi.org/10.1086/491713
[47] Robert, J., Bismuth, R. and Jarlier, V. (2006) Decreased Susceptibility to Glycopeptides in Methicillin-Resistant Staphylococcus aureus: A 20 Year Study in a Large French Teaching Hospital, 1983-2002. Journal of Antimicrobial Chemotherapy, 57, 506-510.
http://dx.doi.org/10.1093/jac/dki486
[48] Lawrence, K.R., Adra, M. and Gillman, P.K. (2006) Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. Clinical Infectious Diseases, 42, 1578-1583.
http://dx.doi.org/10.1086/503839
[49] Perry, C.M. and Jarvis, B. (2001) Linezolid: A Review of Its Use in the Management of Serious Gram-Positive Infections. Drugs, 61, 25-51.
http://dx.doi.org/10.2165/00003495-200161040-00008
[50] Martinez-Aguilar, G., Hammerman, W.A., Mason Jr., E.O. and Kaplan, S.L. (2003) Clindamycin Treatment of Invasive Infections Caused by Community-Acquired, Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus in Children. Pediatric Infectious Disease Journal, 22, 593-598.
http://dx.doi.org/10.1097/01.inf.0000073163.37519.ee
[51] Geddes, A.M., Dwyer, N.S., Ball, A.P. and Amos, R.S. (1977) Clindamycin in Bone and Joint Infections. Journal of Antimicrobial Chemotherapy, 3, 501-507.
http://dx.doi.org/10.1093/jac/3.5.501
[52] Stevens, D.L., Herr, D., Lampiris, H., Hunt, J.L., Batts, D.H., Hafkin, B., et al. (2002) Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. Clinical Infectious Diseases, 34, 1481-1490.
http://dx.doi.org/10.1086/340353